ClinicalTrials.gg
RecruitingNCT04570020Updated Sep 9, 2025

Scleral Lens Fitting Using Wide-Field OCT

An observational study in Keratoconus and Irregular; Contour of Cornea, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Oregon Health and Science University · Observational

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
258
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to see if OCT technology can optimize scleral contact lens fittings. Subjects with keratoconus, post-penetrating keratoplasty (PK), post-LASIK ectasia, post-radial keratotomy (RK), or a variety of anterior surface disorders requiring scleral lens fittings will be considered for enrollment. For each study eye, a clinically-selected scleral lens fit will be compared against an OCT-selected lens fit. The quality of each lens fit will be determined by flourescein exam at the slit lamp. Apical clearance, limbal clearance, conjunctival compression, and lens edge lift will be assessed. A lens that satisfies all four criteria will be considered satisfactory.

02

Conditions studied

  • Keratoconus
  • Irregular; Contour of Cornea

Browse trials for

Keywords

  • Keratoconus (KCN)
  • Irregular Cornea
  • Optical Coherence Tomography (OCT)
03

In context

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's planned enrollment of 258 is above the median of 130 across 97 observational studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 696 studies on the registry; 131 are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 39 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female subjects meeting the eye criteria listed above.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eyes requiring fit for scleral lenses for KCN, post-PK, post-RK, post-LASIK ectasia, or various anterior surface disorders

Exclusion criteria

Exclusion Criteria:

  • Inability to maintain stable fixation for OCT imaging
  • Inability to commit to required visits to complete the study
  • Eyes with concurrent retinal diseases, glaucoma, or other eye conditions that may limit visual outcome
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
258 participants (estimated)
Patient registry
No

Groups and cohorts

  • Clinically-Selected Scleral Lens

    The clinically-selected lens is based on slit lamp assessment. This lens will be compared against an OCT-selected lens.

  • OCT-Selected Scleral Lens

    The OCT-selected lens is based on OCT measurements. This lens will be compared against a clinically-selected lens.

06

What researchers measure

Primary outcomes

  1. Apical Clearance

    Apical clearance of each lens (whether clinically-selected or OCT-selected) will be graded as "acceptable," "too high," or "too low."

    Time frame: 5 years

  2. Limbal Clearance

    Limbal clearance of each lens (whether clinically-selected or OCT-selected) will be graded as "acceptable," "too much," or "too little."

    Time frame: 5 years

  3. Conjunctival Compression

    Conjunctival compression of each lens (whether clinically-selected or OCT-selected) will be graded as "acceptable" or "excessive."

    Time frame: 5 years

  4. Lens Edge Lift

    Lens edge lift for each lens (whether clinically-selected or OCT-selected) will be graded as "acceptable" or "excessive."

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Oregon Health & Science University, Casey Eye Institute
    Portland, Oregon 97239, United States
    Recruiting
    • Humberto Martinez, COT · Contactmartinhu@ohsu.edu · 503-494-7712
    • Denzil Romfh, OD · Contactromfhd@ohsu.edu · 503-494-4351
    • Winston Chamberlain, MD, PhD · Sub investigator
    • Afshan Nanji, MD · Sub investigator
    • Derek Louie, OD · Sub investigator
    • Yan Li, PhD · Sub investigator
    • Richard Stutzman, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.

Of 33 non-industry observational studies under Keratoconus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 204. This study's planned 87 months is above that.

Counting every sponsor, half of 36 studies reached it within 30 months; a quarter within 13 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 30, 2020
StartActual
Sep 23, 2020
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04570020
Responsible party
David Huang (Peterson Professor of Ophthalmology & Professor of Biomedical Engineering, Oregon Health and Science University) — Principal investigator
First posted
Sep 30, 2020
Start date
Sep 23, 2020
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 9, 2025

Study contacts

Humberto Martinez, COT
Contact
martinhu@ohsu.edu
503-494-7712
Denzil Romfh, OD
Contact
romfhd@ohsu.edu
503-494-4351
David Huang, MD, PhD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion